Sector News

UCB and Chiesi enter global license agreement for zampilimab a novel monoclonal antibody for fibrotic lung diseases

December 5, 2021
Life sciences

UCB, a global biopharmaceutical company, and Chiesi Group, the international research-focused pharmaceutical and healthcare group, are pleased to announce that they have entered into an agreement that grants Chiesi a worldwide exclusive license to develop, commercialize and manufacture zampilimab, a clinical stage investigational transglutaminase 2 (TG2) inhibitor with the potential to be an anti-remodelling agent in fibrotic diseases such as Idiopathic Pulmonary Fibrosis (IPF).

“At Chiesi, we are exploring new programs that address the key pathways in the complex disease IPF. The goal is to offer new treatment options that delay or reverse lung function decline in patients suffering from such progressive interstitial lung diseases”, said Thomas Eichholtz, Head of Global Research and Development of Chiesi Group. “This will be the first monoclonal antibody in the Chiesi pipeline, thereby accelerating the company’s entry into biologics and thus diversifies our therapeutic platforms. I am excited at the possibilities of this new asset and pleased that we can benefit from the scientific and technical know-how of UCB”.

Idiopathic Pulmonary Fibrosis is a chronic lung disease in which the tissue of the lungs becomes scarred (fibrosis) and breathing becomes increasingly difficult. It is the most common of the idiopathic interstitial pneumonias and carries a poor prognosis, with median survival ranging from 2.5 to 3.5 years.1,2 Therefore, there is a need for novel treatments that could delay, or reverse, disease progression.

Dhaval Patel, UCB’s Chief Scientific Officer said, “Agreements such as this one are a testament to the calibre of our innovative science and antibody expertise as well as a clear demonstration of the value we are creating through strong research productivity.” He added, “We are confident that Chiesi, a company with an established global presence and a focus on the development of novel drug candidates for the treatment of idiopathic pulmonary fibrosis and other pulmonary fibrotic diseases, will quickly progress zampilimab.”

Monoclonal antibodies are laboratory-produced molecules engineered to serve as substitute antibodies that can modulate the biological activity of a specific target via an antigenetic site. The goal for this potential new treatment would be to ameliorate, if not reverse, the relentless fibrotic process of IPF.

By UCB, Press Release

Source: ucb.com

comments closed

Related News

April 20, 2024

CureVac and MD Anderson Cancer Center partner to develop new cancer vaccines

Life sciences

CureVac and the University of Texas’s MD Anderson Cancer Center have announced a co-development and licensing agreement to develop novel messenger ribonucleic acid (mRNA)-based cancer vaccines. The strategic collaboration will focus on the development of differentiated cancer vaccine candidates in selected haematological and solid tumour indications with high unmet medical needs.

April 20, 2024

FUJIFILM plans $1.2 billion investment in major US manufacturing facility

Life sciences

FUJIFILM Corporation is planning to invest $1.2 billion to expand the planned FUJIFILM Diosynth Biotechnologies manufacturing facility in Holly Springs, North Carolina, US. This news follows the organisation’s announcement of a $2 billion investment in the facility in March 2021. This additional financial boost totals the investment to over $3.2 billion, FUJIFILM confirmed.

April 20, 2024

Sanofi cuts staff in Belgium as early-stage research dwindles

Life sciences

Sanofi’s global restructuring and downsizing is now fully underway, with layoffs stretching to the company’s Belgian offices. Belgian newspaper De Tijd reports that 67 employees have been laid off at a site in Ghent and 32 jobs are on the chopping block at Sanofi’s Belgium HQ in Diegem.

How can we help you?

We're easy to reach